-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Geneva, September 24, 2021/PRNewswire/ - MedAlliance and its Japanese partner MDK Medical have completed the clinical trial of its new sirolimus drug-eluting balloon (DEB) SELUTION SLR™ for the treatment of peripheral arterial disease (PAD) Research recruitment
MedAlliance announces completion of enrollment in Japanese SELUTION SLR(TM) Study
The study involved 133 patients in 13 research centers in Japan
Jeffrey B.
SELUTION SLR received CE mark approval for the treatment of peripheral artery disease and coronary artery disease in February 2020 and May 2020, respectively
In August 2021, the first patient out of more than 3,000 patients was recruited into a groundbreaking randomized controlled coronary study that compared SELUTION SLR with Limus drug-eluting stent [DES]
MedAlliance's DEB technology involves a unique microreservoirs (MicroReservoirs) made of a mixture of biodegradable polymers and anti-restenosis drug Sirolimus
1.
About MedAlliance
MedAlliance is a private medical technology company
Source: MedAlliance